Patents Represented by Attorney, Agent or Law Firm Elizabeth M. Anderson
  • N-substituted glutamic acid derivatives with interleukin-1.beta. converting enzyme inhibitory activity
    Patent number: 5932549
    Abstract: The present invention relates to N-substituted derivatives of glutamic acid of pharmaceutical interest, to pharmaceutical compositions which include compounds of the invention and pharmaceutically acceptable carriers, to methods of their preparation, and to their use in purification of interleukin-1.beta. converting enzyme (ICE).
    Type: Grant
    Filed: April 27, 1998
    Date of Patent: August 3, 1999
    Assignees: Warner-Lambert Company, BASF Aktiengesellschaft
    Inventors: Hamish John Allen, Subhashis Banerjee, Kenneth Dale Brady, John Cooke Hodges, Catherine Rose Kostlan, Robert Vincent Talanian
  • Substituted quinolines and isoquinolines as calcium channel blockers, their preparation and the use thereof
    Patent number: 5932573
    Abstract: The present invention relates to novel substituted quinolines and isoquinolines and derivatives thereof useful in the treatment of neurological disorders. Methods of preparing the compounds, intermediates useful in the preparation and pharmaceutical compositions containing the compounds are also included. The compounds are useful in treating pain, cerebral ischemia, and other cerebrovascular disorders.
    Type: Grant
    Filed: March 17, 1998
    Date of Patent: August 3, 1999
    Assignee: Warner-Lambert Company
    Inventor: Po-Wai Yuen
  • Cyclic amino acids as pharmaceutical agents
    Patent number: 5929088
    Abstract: Novel cyclic amino acids of formula (Ia) or (Ib) are disclosed and are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, and neuropathological disorders.
    Type: Grant
    Filed: May 18, 1998
    Date of Patent: July 27, 1999
    Assignee: Warner-Lambert Company
    Inventors: David C. Horwell, Justin S. Bryans, Clare O. Kneen, Giles Ratcliffe
  • Butenolide endothelin antagonists
    Patent number: 5922759
    Abstract: Novel nonpeptides characterized as having a carbarimic group which are antagonists of endothelin I are described, as well as methods for their preparation and pharmaceutical compositions containing the same. The compounds as useful in treating elevated levels of endothelin and are therefore used in the treatment of hypertension, myocardial infarction, diabetes, cerebral vasospasm, cirrhosis, septic shock, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, chronic and acute renal failure, preeclamnpsia, atherosclerotic disorders including Raynaud's disease and restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, hemorrhagic shock, stroke, head injury, and ischemic bowel syndrome.
    Type: Grant
    Filed: December 15, 1997
    Date of Patent: July 13, 1999
    Assignee: Warner-Lambert Company
    Inventors: William C. Patt, Bill R. Reisdorph, Joseph T. Repine
  • Endothelin antagonists
    Patent number: 5922681
    Abstract: Antagonists of endothelin are described, as well as methods of using them and pharmaceutical compositions containing them. These compounds are useful in controlling hypertension, myocardial infarction, pulmonary hypertension, angina, metabolic, endocrinological, and neurological disorders, congestive heart failure, septic or endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, preeclampsia, and diabetes.
    Type: Grant
    Filed: September 14, 1992
    Date of Patent: July 13, 1999
    Assignee: Warner-Lambert Company
    Inventors: Annette Marian Doherty, David Charles Rees
  • Small molecule biaryl compounds as inhibitors of endothelin converting enzyme
    Patent number: 5891892
    Abstract: Novel small molecular biaryl compounds as inhibitors of endothelin converting enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, myocardial ischemia, cerebral vasospasm, cerebral ischemia, cerebral infarction, cirrhosis, septic shock, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, hemorrhagic shock, ischemic bowel disease, stroke, benign prosthatic hyperplasia (BPH), and diabetes.
    Type: Grant
    Filed: October 14, 1997
    Date of Patent: April 6, 1999
    Assignee: Warner-Lambert Company
    Inventors: Xue-Min Cheng, Mark Alan Massa, William Chester Patt
  • Indolocarbazole imides and the use thereof
    Patent number: 5883114
    Abstract: The present invention is concerned with the use of indolocarbazole imides of the general formula (I): ##STR1## for the preparation of pharmaceutical compositions for the treatment and/or prevention of cancer, virus diseases (for example HIV infections), heart and blood vessel diseases (for example high blood pressure, thromboses, heart rhythm disturbances and atheroscleroses), bronchopulmonary diseases, degenerative diseases of the central nervous system (for example Alzheimer's disease), inflammatory diseases (for example rheumatism and arthritis), diseases of the immune system (for example allergies), as well as psoriasis and for use as immune suppressives; as well as new compounds of general formula (I).
    Type: Grant
    Filed: February 15, 1995
    Date of Patent: March 16, 1999
    Assignee: Goedecke Aktiengesellschaft
    Inventors: Jurgen Kleinschroth, Christoph Schachtele, Johannes Hartenstein, Claus Rudolph, Hubert Barth, Julian Aranda, Hans Jurgen Betche
  • Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
    Patent number: 5874426
    Abstract: A novel series of substituted quinoxaline 2,3-diones of Formula I ##STR1## useful as neuroprotective agents are taught. Novel intermediates, processes of preparation, and pharmaceutical compositions containing the compounds are also taught. The compounds are glutamate antagonists and are useful in the treatment of stroke, cerebral ischemia, or cerebral infarction resulting from thromboembolic or hemorrhagic stroke, cerebral vasospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, seizure disorders, pain, Alzheimer's, Parkinson's, and Huntington's Diseases.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 23, 1999
    Assignee: Warner-Lambert Company
    Inventors: Brian Edward Kornberg, Sham Nikam, Michael Francis Rafferty, Po-Wai Yuen
  • Quinazolinone derivatives as cholecystokinin (CCK) ligands
    Patent number: 5869665
    Abstract: Novel quinazolinone derivatives with good binding affinity for the CCK-A and CCK-B receptors, pharmaceutical compositions containing them, methods of using them and a novel process for their preparation are taught. The compounds are useful agents to suppress appetite, reduce gastric acid secretion, and the like.
    Type: Grant
    Filed: April 8, 1997
    Date of Patent: February 9, 1999
    Assignee: Warner-Lambert Company
    Inventor: Janak Khimchand Padia
  • Tachykinin antagonists
    Patent number: 5856354
    Abstract: The invention concerns tachykinin antagonists. The compounds are neopeptides which have utility in treating disorders mediated by tachykinins. Such disorders are respiratory, inflammatory, gastrointestinal, ophthalmic, allergies, pain, vascular, diseases of the central nervous system, and migraine. Methods of preparing compounds and novel intermediates are also included. The compounds are expected to be especially useful in asthma and rheumatoid arthritis.
    Type: Grant
    Filed: October 17, 1997
    Date of Patent: January 5, 1999
    Assignee: Warner-Lambert Company
    Inventors: David Christopher Horwell, William Howson, Martyn Clive Pritchard, Edward Roberts, David Charles Rees
  • Cholecystokinin antagonists, their preparation and therapeutic use
    Patent number: 5846942
    Abstract: Novel cholecystokinin antagonists useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further, the compounds are antianxiety agents and antiulcer agents. They are agents useful for preventing the response to the withdrawal from chronic treatment with use of nicotine, diazepam, alcohol, cocaine, coffee, or opioids. The compounds of the invention are also useful in treating and/or preventing panic. Also disclosed are pharmaceutical compositions and methods of treatment using the antagonists as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds in diagnostic compositions.
    Type: Grant
    Filed: September 9, 1996
    Date of Patent: December 8, 1998
    Assignee: Warner-Lambert Company
    Inventors: David Christopher Horwell, Edward Roberts, Ann Holmes, Janak Khimchand Padia, William Howard Roark, Bruce David Roth, Bharat Kalidas Trivedi, Jurgen Kleinschroth
  • 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
    Patent number: 5840751
    Abstract: The present invention relates to novel 5,6-dihydropyrone derivatives and related structures which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The 5,6-dihydropyrone derivatives are useful in the development of therapies for the treatment of bacterial and viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of multifunctionalized 5,6-dihydropyrones and of related structures.
    Type: Grant
    Filed: October 12, 1994
    Date of Patent: November 24, 1998
    Assignee: Warner-Lambert Company
    Inventors: Edmund Lee Ellsworth, Elizabeth Lunney, Bradley Dean Tait
  • Pyrone derivatives as protease inhibitors and antiviral agents
    Patent number: 5808062
    Abstract: The present invention relates to novel tri- and tetrasubstituted pyrones and related structures which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The pyrone derivatives are useful in the development of therapies for the treatment of bacterial and viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of multifunctionalized pyrones and of related structures.
    Type: Grant
    Filed: October 12, 1994
    Date of Patent: September 15, 1998
    Assignee: Warner-Lambert Company
    Inventors: John Michael Domagala, Edmund Lee Ellsworth, Elizabeth Lunney, Daniel Fred Ortwine, Kimberly Suzanne Para, Josyula Venkata Nagendra Vara Prasad, Tomi Sawyer, Bradley Dean Tait
  • Phosphonamide ACAT inhibitors
    Patent number: 5807846
    Abstract: The present invention is directed to compounds useful for the regulation of cholesterol of Formula I, methods for using them and pharmaceutical compositions thereof, ##STR1## wherein Ar and Ar.sup.1 are each independently selected from unsubstituted or substituted phenyl which substituents are from 1-5 in number and are each independently selected from alkyl, alkoxy, hydroxy, halogen, nitro, trifluoromethyl, COOH, and COOalkyl;X is --NH--, --O--, --S--, or --(CH.sub.2).sub.0-4 --, andR is hydrogen, alkyl, or phenyl.
    Type: Grant
    Filed: June 24, 1997
    Date of Patent: September 15, 1998
    Assignee: Warner-Lambert Company
    Inventors: William Howard Roark, Bruce David Roth
  • Methods for treating anxiety and panic
    Patent number: 5792796
    Abstract: The instant invention is novel uses of known cyclic amino acids. Such compounds as gabapentin are useful in the treatment of anxiety and in the treatment and/or prevention of panic attacks.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: August 11, 1998
    Assignee: Warner-Lambert Company
    Inventors: Geoffrey Neil Woodruff, Nicolas Steven Gee, Lakhbir Singh, Jason Peter Brown
  • 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
    Patent number: 5789440
    Abstract: The present invention relates to novel 5,6-dihydropyrone derivatives and related structures which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The 5,6-dihydropyrone derivatives are useful in the development of therapies for the treatment of bacterial and viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of multifunctionalized 5,6-dihydropyrones and of related structures.
    Type: Grant
    Filed: October 12, 1994
    Date of Patent: August 4, 1998
    Assignee: Warner-Lambert Company
    Inventors: Edmund Lee Ellsworth, Elizabeth Lunney, Bradley Dean Tait
  • Cell Line for the rapid expression of functional calcium channels
    Patent number: 5770447
    Abstract: The instant invention provides a stable cell line, 34893 2L, for the rapid functional expression of high voltage activated calcium channels.
    Type: Grant
    Filed: September 4, 1997
    Date of Patent: June 23, 1998
    Assignee: Warner-Lambert Company
    Inventor: James David Offord
  • Substituted quinolines and isoquinolines as calcium channel blockers, their preparation and the use thereof
    Patent number: 5767129
    Abstract: The present invention relates to novel substituted quinolines and isoquinolines and derivatives thereof useful in the treatment of neurological disorders. Methods of preparing the compounds, intermediates useful in the preparation and pharmaceutical compositions containing the compounds are also included. The compounds are useful in treating pain, cerebral ischemia, and other cerebrovascular disorders.
    Type: Grant
    Filed: August 13, 1996
    Date of Patent: June 16, 1998
    Assignee: Warner-Lambert Company
    Inventor: Po-Wai Yuen
  • Tachykinin antagonists
    Patent number: 5767088
    Abstract: The small compounds of the instant invention are tachykinin antagonists. The compounds are highly selective and functional NK.sub.3 antagonists expected to be useful in the treatment of pain, depression, anxiety, panic, schizophrenia, neuralgia, addiction disorders, inflammatory diseases, gastrointestinal disorders, vascular disorders, and neuropathological disorders.
    Type: Grant
    Filed: September 4, 1996
    Date of Patent: June 16, 1998
    Assignee: Warner-Lambert Company
    Inventors: David Christopher Horwell, William Howson, Martyn Clive Pritchard, Jennifer Raphy
  • Alpha-mercaptoacrylic acid derivatives having calpain inhibitory activity
    Patent number: 5760048
    Abstract: The invention covers a novel series of .alpha.-mercaptoacrylic acid derivatives that inhibit both calpain I and calpain II with a high affinity and selectivity. The compounds are useful in the treatment of neurodegenerative disorders including cerebrovascular disorders, brain injury, spinal cord, and peripheral nerve injury, cardiac infarction, cataracts, inflammation, restenosis, muscular dystrophy, and platelet aggregation. Pharmaceutical compositions, methods of using processes for preparing and novel intermediates useful in the processes are also disclosed.
    Type: Grant
    Filed: April 19, 1996
    Date of Patent: June 2, 1998
    Assignee: Warner-Lambert Company
    Inventors: Kevin Ka-Wang Wang, Po-Wai Yuen